3rd Party Medical Device Industry News

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Deciphera Pharmaceuticals notes the article titled “Vimseltinib versus placebo for [...]

By |2024-06-03T11:43:56+00:00June 3, 2024|3rd Party Medical Device Industry News|Comments Off on Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Go to Top